Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC fines weight-loss marketers

This article was originally published in The Tan Sheet

Executive Summary

Advanced Patch Technology and its distributor Buckhead Marketing & Distribution will forfeit $110,539 in estimated profits for allegedly falsely marketing its Peel Away the Pounds weight-loss patch, according to the Federal Trade Commission. FTC took issue with claims directed at overseas consumers that said the patch would cause substantial weight loss in all users. FTC also alleges the marketers violated a 2004 consent order under which the firms agreed to stop making the deceptive claims and paid more than $1 million in consumer redress (1"The Tan Sheet" March 15, 2004, p. 10). Under the current settlement, the firms are barred from selling and advertising weight-loss products, making unsubstantiated claims or assisting others with these tasks, FTC says Sept. 30

You may also be interested in...



FTC Weight-Loss Settlements Include Over $3 Mil. In Fines, Redress

The Federal Trade Commission announced a $1.2 mil. settlement with the manufacturer, marketers and endorser of a weight-loss patch containing seaweed extract March 10

While Opening Dietary Ingredient Portfolio Wider, DuPont Opens Door On Online Supply Store

In its “robust, holistic hub” online, firms in the VMS product supply chain can determine their needs, “by product, solution or delivery formats,” and use a “comprehensive and unique portfolio” to “turn natural sources into shelf-ready products.”

Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy

Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel